Catalytic transfer hydrogenation and anticancer activity of arene-ruthenium compounds incorporating bi-dentate precursors

Yu Hsiang Chang, Wohn Jenn Leu, Amitabha Datta, Hung Chang Hsiao, Chia Her Lin, Jih Hwa Guh, Jui Hsien Huang

研究成果: Article

12 引文 斯高帕斯(Scopus)

摘要

Ruthenium based organometallic compounds are presently a subject of great attention as anticancer drugs and appear to work reasonably well on tumor cells. We develop a series of mononuclear arene-ruthenium compounds incorporating N,O and N,N bidentate ligands, and their activity as anticancer drugs against human hormone-refractory metastatic prostate cancer (HRMPCs) cell lines are investigated. The ruthenium compounds also act as effective catalysts in the transfer hydrogenation of the -C=O- → -CH(OH)- system. Three types of ligands, namely, sodium glutamate, C4H3NH(2-CH2NHtBu), and C4H3NH(2-CH=NR) are separately coupled with [(η6-cymene)RuCl2]2 (1) (cymene = 4-isopropyltoluene) to synthesize five Ru-derivatives: [(η6-cymene)RuCl(κ2-N,O-OOCCHNH2CH2CH2COOH)] (2), {(η6-cymene)RuCl[C4H3N(2-CH2NHtBu)]} (3), {(η6-cymene)RuCl[C4H3N(2-CH=NCH2Ph)]} (4), {(η6-cymene)RuCl{C4H3N[2-CH=NCH2(C4H7O)]}} (5) and {(η6-cymene)RuCl[C4H3N(2-CHnBuNHCH2(C4H7O))]} (7). To the best of our knowledge, the aforementioned Ru compounds are not only characterized by 1H and 13C NMR spectroscopy, but for the first time their structures have been established by single crystal X-ray diffractometry. Compound 4 influences a concentration-dependent apoptosis in PC-3 cells and initiates the conversion rate in transfer hydrogenation.

原文English
頁(從 - 到)16107-16118
頁數12
期刊Dalton Transactions
44
發行號36
DOIs
出版狀態Published - 2015 八月 4

All Science Journal Classification (ASJC) codes

  • Inorganic Chemistry

指紋 深入研究「Catalytic transfer hydrogenation and anticancer activity of arene-ruthenium compounds incorporating bi-dentate precursors」主題。共同形成了獨特的指紋。

  • 引用此